Latest news with #RM57.5

BusinessToday

Alpha IVF Reported RM57 Million PATMI For FY25, Looks Set For Philippine Expansion

Alpha IVF Group Berhad achieved its highest-ever profit after tax and minority interests (PATMI) of RM57.5 million in the financial year ended 31 May 2025 (FY2025), a 8.5% increase from RM52.9 million in the previous year. The strong bottom-line performance was supported by revenue growth of 5.5% to RM176.8 million in FY2025 from RM167.6 million in the previous year, led by the Group's Malaysia operations, particularly the foreign patient segment. Malaysia operations contributed RM157.2 million, or 88.9% of the Group's total revenue in FY2025, a 16.0% increase from RM135.5 million in the previous year, or 80.9% of the Group's total revenue. The Group's Singapore operations contributed the remaining RM19.6 million. For Malaysia operations, local demand remained stable, while foreign patient revenue regained momentum this quarter, with all key markets, including China, Indonesia, and Singapore, recording an upward trend. The contribution of foreign patients to Malaysia's operations saw significant growth in FY2025, rising to RM110.1 million or 70.0% of total revenue, from RM81.8 million or 60.4% in FY2024. In the fourth quarter ended 31 May 2025 (4Q25), the Group's revenue rose 7.0% year-on-year to RM50.0 million from RM46.7 million previously, while PATMI saw a 14.7% increase to RM16.1 million from RM14.0 million in the corresponding quarter of the previous year. The Group declared a second interim dividend of 0.50 sen per share in respect of FY2025, payable on 29 August 2025. Together with the first interim dividend of 0.50 sen per share paid on 31 December 2024, the total dividends for FY2025 amount to 1.00 sen per share, representing a payout of RM48.6 million or 84.6% of PATMI. This is well above the Group's commitment to distribute at least 60% of its annual PATMI for shareholders. The medical outfit announced that it is establishing a new, full-fledged fertility treatment centre in Tuguegarao, Philippines, marking the Group's second planned facility in the country. The group said the centre will provide minimally invasive surgery in Gynaecology, which is expected to contribute significantly to the centre's revenue. Related